

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 72929

Title: The development of CRISPR/Cas technology in potential clinical applications

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06181567

Position: Peer Reviewer

Academic degree: MSc

Professional title: Academic Research, Lecturer

Reviewer's Country/Territory: Ethiopia

Author's Country/Territory: China

Manuscript submission date: 2021-11-03

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-11-04 10:24

Reviewer performed review: 2021-11-07 08:05

Review time: 2 Days and 21 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The review gives a new overview related to the current advanced scientific pieces of evidences that CRISPR/Cas technology is being contributed to clinical practice. The conclusion of the review provides a clear summary of the topic. But the Author has to discuss the recent developments of the technology in detail. So the review seems to be limited in quantity.

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 72929

Title: The development of CRISPR/Cas technology in potential clinical applications

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 00057299

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Professor

Reviewer's Country/Territory: South Korea

Author's Country/Territory: China

Manuscript submission date: 2021-11-03

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-11-04 06:27

Reviewer performed review: 2021-11-15 06:37

Review time: 11 Days

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The present manuscript reviews almost all issues regarding clinical applications of CRISPR/Cas genome editing system. The manuscript is relatively well written. However, it has some concerns to be corrected. 1. Figure 1 gives just collateral activity of Cas9, Cas12, Cas13. This figure must include general mechanisms of gene editing by CRISPR/Cas in detail. 2. The authors well reviewed regarding diagnostic applications. However, a review for tumor pathogenesis would like to include detect epigenetic changes as well as genetic changes. 3. Therapeutic applications are not enough discussed. If the authors don't want to add sentences for therapeutic applications, they can add figure and/or table for delivery strategies or clinical trials. Alternatively, they can remove section for therapeutic applications. 4. In 'Challenges facing the application of CRISPR/Cas technology' section, the authors don't suggest solutions to overcome 'off target effect' or 'safety issues'. This point might be due to insufficient review for therapeutic applications.